A recent study investigated epicutaneous immunisation with the AntpSIIN OVA CD8 (AntpSIIN) fusion peptide, where topical application of AntpSIIN induced potent CTL responses in mice and with the adjuvant CpG conferred tumour protection against E.G7-OVA tumour cells [22]. This evidence concerns the gene CD8A and neoplasm.